154 related articles for article (PubMed ID: 15148627)
41. [The action and toxicity of taxanes].
Lipp HP; Bokemeyer C
Pharm Unserer Zeit; 2005; 34(2):128-37. PubMed ID: 15803797
[No Abstract] [Full Text] [Related]
42. Docetaxel in androgen-independent prostate cancer: an update.
Khan MA; Carducci MA; Partin AW
BJU Int; 2004 Dec; 94(9):1209-10. PubMed ID: 15610087
[No Abstract] [Full Text] [Related]
43. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate.
Kumar P; Perrotti M; Weiss R; Todd M; Goodin S; Cummings K; DiPaola RS
J Clin Oncol; 2004 May; 22(10):1909-15. PubMed ID: 15143084
[TBL] [Abstract][Full Text] [Related]
44. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
[TBL] [Abstract][Full Text] [Related]
46. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Sleijfer S; Stoter G
Nat Clin Pract Oncol; 2005 Feb; 2(2):70-1. PubMed ID: 16264874
[No Abstract] [Full Text] [Related]
47. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11).
Boisseau M; Bugat R; Mahjoubi M
Eur J Cancer; 1996 Apr; 32A(4):737-8. PubMed ID: 8695285
[No Abstract] [Full Text] [Related]
48. Ductal variant of adenocarcinoma prostate responding to docetaxel--a case report.
Paterson C; Correa PD; Russell JM
Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):617. PubMed ID: 20542674
[No Abstract] [Full Text] [Related]
49. Tumor lysis syndrome in a nonsmall cell lung cancer.
Noyes AM; Lonial K; Siegel RD
Conn Med; 2014 Aug; 78(7):421-3. PubMed ID: 25195308
[TBL] [Abstract][Full Text] [Related]
50. The continuing challenge of hormone-refractory prostate cancer.
Sartor O
Clin Genitourin Cancer; 2006 Mar; 4(4):238-9. PubMed ID: 16729904
[No Abstract] [Full Text] [Related]
51. Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature.
Drakos P; Bar-Ziv J; Catane R
Am J Clin Oncol; 1994 Dec; 17(6):502-5. PubMed ID: 7977169
[TBL] [Abstract][Full Text] [Related]
52. Tumor lysis syndrome and metastatic melanoma.
Meeks MW; Hammami MB; Robbins KJ; Cheng KL; Lionberger JM
Med Oncol; 2016 Dec; 33(12):134. PubMed ID: 27807723
[TBL] [Abstract][Full Text] [Related]
53. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.
Ignaszewski M; Kohlitz P
Am J Emerg Med; 2017 Sep; 35(9):1384.e1-1384.e2. PubMed ID: 28587951
[TBL] [Abstract][Full Text] [Related]
54. Extravasation of docetaxel: a red hand syndrome.
Barceló R; Viteri A; Muñoz A; Carrera S; Rubio I; López-Vivanco G
Arch Dermatol; 2005 Oct; 141(10):1326-7. PubMed ID: 16230582
[No Abstract] [Full Text] [Related]
55. Lymphocutaneous nocardiosis in a lymphopenic breast cancer patient under treatment with docetaxel.
Apostolakis S; Chalkiadakis I; Ventouri M; Maraki S; Tsoussis S
Breast J; 2005; 11(6):469. PubMed ID: 16297095
[No Abstract] [Full Text] [Related]
56. [A case of esophageal cancer patient who developed tumor lysis syndrome after chemotherapy].
Tokunou K; Takeda S; Yoshino S; Nishimura T; Oka M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2030-2. PubMed ID: 19106513
[TBL] [Abstract][Full Text] [Related]
57. Alcohol intoxication with the new formulation of docetaxel.
Mirza A; Mithal N
Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):560-1. PubMed ID: 21571513
[No Abstract] [Full Text] [Related]
58. A shortened docetaxel desensitization protocol for use in special cases.
Zirbs M; Seifert F; Zink A; Ring J; Brockow K
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):391-3. PubMed ID: 22339786
[No Abstract] [Full Text] [Related]
59. Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature.
Taira F; Horimoto Y; Saito M
Breast Cancer; 2015 Nov; 22(6):664-8. PubMed ID: 23420376
[TBL] [Abstract][Full Text] [Related]
60. Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes.
Sawada Y; Sugita K; Kabashima R; Nakamura M; Tokura Y
J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1333-5. PubMed ID: 19453796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
